The most discussed GI effect of GLP-1 is delayed gastric emptying. Constipation, nausea and dyspepsia were recorded in trials, dose-dependently.
GLP-1 slows gastric emptying — part of the pharmacology being studied. For bowel motility the picture is mixed: both constipation and diarrhea appear in trials, depending on dose and individual response.
GI effects intensify during titration to higher doses.
Starting low and stepping up slowly is standard in trial protocols.
Fluid deficit worsens constipation when appetite drops.
GI effects typically ease as the gut adapts to a stable dose.
A question for the researcher/physician. This page is not medical advice.